Clinical Trial: Neuroblastoma

ANBL1232 Non-High Risk Neuroblastoma Study (PRO00002135)

Full Name

COG ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma


The current standard of treatment for non-high risk neuroblastoma includes either surgery alone to remove the tumor tissue, or surgery and chemotherapy.  People with non-high risk neuroblastoma generally respond well to treatment, and the majority of patients can be treated with standard therapy. Patients who choose to take part will be assigned to one of 3 groups. Group A will be observed and will not have surgery to remove the tumor tissue. The goal for those assigned to group A is to see if participants with very low-risk neuroblastoma can be observed instead of having surgery and still have a successful outcome.   Those assigned to Group B have a tumor in one place and have good biologic features. The goal for those assigned to group B is to see if they can be observed, instead of having surgery and/or receiving chemotherapy, and still have successful outcomes. Those assigned to Group C have a tumor that involves the liver. The goal of group C is to determine if participants who have symptoms would benefit from starting chemotherapy immediately. Another goal of group C is to see if using a scoring system to decide when to start and stop chemotherapy will help tailor the amount of therapy needed to treat each participant’s cancer successfully. 


Inclusion Criteria
Inclusion Criteria-including but may not be limited to: Must be less than 12 months of age at diagnosis with INRG Stage L1 or less than 18 months of age at diagnosis with INRG Stage L2 or Stage Ms Neuroblastoma Must be newly diagnosed MYCN non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma (Only patients with MYCN non-amplified tumors are eligible for this study) Must not have had any prior radiotherapy or chemotherapy (dexamethasone is allowed)